Skip to content

Current ratio at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
0.9×0.0×
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
4.9×-6.1×
Viatris logo
ViatrisVTRS
1.6×-0.1×
AMP
Amphastar PharmaceuticalsAMPH
3.9×+0.9×
AptarGroup logo
AptarGroupATR
1.7×+0.4×
AbbVie logo
AbbVieABBV
0.8×0.0×

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×

Where this comes from

Calculated from Aquestive Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s current ratio?
Aquestive Therapeutics, Inc. (AQST) reported current ratio of 4.1× in Q1 2026.
How has Aquestive Therapeutics, Inc.'s current ratio changed year-over-year?
Aquestive Therapeutics, Inc.'s current ratio decreased by 15.9% year-over-year, from 4.9× to 4.1×.
What is the long-term trend for Aquestive Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s current ratio has grown at a 8.2% compound annual growth rate (CAGR), from 2.1× to 3.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.